Jan Mareš

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex^®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Alena Novotná, Jan Mareš, S. Ratcliffe et al. · European Journal of Neurology · 2011 · 464 citations

Medicine, Neurology, Pharmacology +17

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

Richard Langford, Jan Mareš, Alena Novotná et al. · Journal of Neurology · 2012 · 297 citations

Medicine, Pharmacology, Pharmacotherapy +16

Long-term safety and efficacy of teriflunomide

Paul O’Connor, Mark S. Freedman, Aaron Miller et al. · Neurology · 2016 · 126 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

CSF markers of neurodegeneration in Parkinson’s disease

Hana Přikrylová Vranová, Jan Mareš, Martin Nevrlý et al. · Journal of Neural Transmission · 2010 · 66 citations

Life Sciences, Neurology, Neuroscience +14

Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia

Hana Přikrylová Vranová, Eva Hényková, Michaela Kaiserová et al. · Journal of the Neurological Sciences · 2014 · 56 citations

Medicine, Neurology, Neuroscience +17